序号 |
标题 |
次数 |
作者 |
发布时间 |
84241 |
3-硝铵基-6-(1H-四唑-5-基)-[1,2,4]三唑[4,3-b][1,2,4,5]四嗪羟胺盐(TATTN·NH3OH) |
117 |
WYQ |
2024-11-27 |
84242 |
3-硝铵基-6-(1H-四唑-5-基)-[1,2,4]三唑[4,3-b][1,2,4,5]四嗪铵盐(TATTN·NH4) |
104 |
WYQ |
2024-11-27 |
84243 |
HA-ASP-CYS-Gd-DOTA ,透明质酸为载体的靶向肿瘤的大分子T1钆基造影剂 |
120 |
kx |
2024-11-27 |
84244 |
CAS:3001301-68-1;DOTA(单酰胺)-OH;DOTA(Monoamides)-OH |
91 |
zcy |
2024-11-27 |
84245 |
DOTA NOC acetate,619300-53-7 |
118 |
zyl |
2024-11-27 |
84246 |
DOTA-SC691-6KL,DOTA偶联卤素取代物 |
97 |
kx |
2024-11-27 |
84247 |
不对称炔丙基取代(+)-Citralis-Propargyl |
96 |
WYQ |
2024-11-27 |
84248 |
不对称炔丙基取代(+)-Phenoxanol-Propargyl |
68 |
WYQ |
2024-11-27 |
84249 |
CAS:250612-06-7;DOTA-RGD探针二聚体;dota-glu[cyclo(arg-gly-asp-d-phe-lys)]2 |
81 |
zcy |
2024-11-27 |
84250 |
不对称炔丙基取代(-)-AMG 837 |
84 |
WYQ |
2024-11-27 |
84251 |
PEG-G5.NH2-FITC-DOTA(Gd)-Monalizumab/IPH4301纳米探针 |
82 |
kx |
2024-11-27 |
84252 |
不对称炔丙基取代(+)-Phenoxanol-Propargyl |
74 |
WYQ |
2024-11-27 |
84253 |
2125661-62-1;Butyne-DOTA;白色固体 |
75 |
zcy |
2024-11-27 |
84254 |
不对称炔丙基取代(-)-AMG 837 |
124 |
WYQ |
2024-11-27 |
84255 |
DOTA-t-Bu ester , 1-(乙氧羰甲基)-4,7,10-三(叔丁氧羰甲基)-1,4,7,10-四氮杂环十二烷 |
104 |
kx |
2024-11-27 |
84256 |
螯合剂多肽,cyclo(RGDFK(DOTA)) |
170 |
zyl |
2024-11-27 |
84257 |
DOTA-Ala-Ala-COOH |
80 |
zyl |
2024-11-27 |
84258 |
3-硝铵基-6-(1H-四唑-5-基)-[1,2,4]三唑[4,3-b][1,2,4,5]四嗪肼盐(TATTN·N2H4) 1. 基本信息 |
94 |
WYQ |
2024-11-27 |
84259 |
DOTA-EB-TMTP , 双功能螯合剂DOTA修饰多肽TMTP1 ,DOTA-EB-NVVRQ |
135 |
kx |
2024-11-27 |
84260 |
3-硝铵基-6-(1H-四唑-5-基)-[1,2,4]三唑[4,3-b][1,2,4,5]四嗪(TATTN) 1. 基本信息 |
105 |
WYQ |
2024-11-27 |
84261 |
PSMA IandT,DOTA-多肽分子探针 |
121 |
zyl |
2024-11-27 |
84262 |
不对称炔丙基取代柠檬腈 (-)-Citralis Nitrile-Propargyl |
168 |
WYQ |
2024-11-27 |
84263 |
聚乙二醇与壳聚糖接枝抗菌肽大分子偶联物(CS-PEG-WW11) |
183 |
WYQ |
2024-11-27 |
84264 |
DOTA-NAPA mide , DOTA偶联α-MSH类似物 |
93 |
kx |
2024-11-27 |
84265 |
端基被炔化抗菌性多肽(WW11-Alk) |
98 |
WYQ |
2024-11-27 |
84266 |
修饰有炔基的铂纳米粒子(Pt NPs-Alk) |
154 |
WYQ |
2024-11-27 |
84267 |
不对称炔丙基取代硫喷妥英(+)-Thiopental-Propargyl |
94 |
WYQ |
2024-11-27 |
84268 |
炔丙基修饰的马蹄金素(MTS)衍生物 |
98 |
WYQ |
2024-11-27 |
84269 |
DOTA类双功能螯合剂(DOTA-Peptide) |
191 |
kx |
2024-11-27 |
84270 |
1610950-41-8,DOTA Methyltetrazine |
115 |
zyl |
2024-11-27 |
84271 |
端炔功能化的温度敏感聚合物 |
219 |
WYQ |
2024-11-27 |
84272 |
DSPE-PEG2000进行偶联螯合剂DOTA , DSPE-PEG2000-DOTA |
170 |
kx |
2024-11-27 |
84273 |
炔基化修饰的L-保护丝氨酸 |
167 |
WYQ |
2024-11-27 |
84274 |
DOTA标记多肽,DOTA-cyclo(RGDyK) |
114 |
zyl |
2024-11-27 |
84275 |
端基炔化次微米二氧化硅 |
100 |
WYQ |
2024-11-27 |
84276 |
DOTA mono-NHS ester,CAS:170908-81-3,轮环藤宁四乙酸活性酯 |
111 |
zyl |
2024-11-27 |
84277 |
DOTA偶联聚吡咯纳米粒子 ,DOTA-PPy |
116 |
kx |
2024-11-27 |
84278 |
DOTA-NHS Ester(DOTA-活性酯),170908-81-3 |
185 |
zyl |
2024-11-27 |
84279 |
CPGD-G3-DOTA ,树枝状大分子造影剂 |
99 |
kx |
2024-11-27 |
84280 |
天然产物齐墩果酸进行炔基化修饰(OA-alkyne) |
221 |
WYQ |
2024-11-27 |
84281 |
末端炔基功能化的硫醇修饰的金纳米粒 |
165 |
WYQ |
2024-11-27 |
84282 |
MWCNT/PEI-FI-DOTA(Gd)-mPEG2K |
143 |
kx |
2024-11-27 |
84283 |
炔基修饰杯芳烃,杯芳烃分子骨架上通过化学反应引入炔基基团的功能化衍生物 |
176 |
WYQ |
2024-11-27 |
84284 |
DOTA-NOC,FC-2154,619300-53-7多肽 |
116 |
zyl |
2024-11-27 |
84285 |
DOTA-Biotin-Sarcosine(DOTA-生物素-肌氨酸) |
131 |
zcy |
2024-11-27 |